A Phase 1 interventional study of DWJ1351 and Co-administration of Sevikar (Olmesartan/Amlodipine) and Crestor (Rosuvastatin) in Healthy, sponsored by Daewoong Pharmaceutical Co. LTD.. Status unknown. Open to male participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-01-28.
Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 1, Interventional, and Basic science
The purpose of this study is to compare the safety and pharmacokinetic characteristics of combination of amlodipine, olmesartan and rosuvastatin and DWJ1351 in healthy male volunteers
Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 196 studies on the registry; 33 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Sevikar (Olmesartan/Amlodipine) and Crestor (Rosuvastatin) followed by DWJ1351
Drug: DWJ1351 · Drug: Co-administration of Sevikar (Olmesartan/Amlodipine) and Crestor (Rosuvastatin)
DWJ1351 followed by Sevikar (Olmesartan/Amlodipine) and Crestor (Rosuvastatin)
Drug: DWJ1351 · Drug: Co-administration of Sevikar (Olmesartan/Amlodipine) and Crestor (Rosuvastatin)
AUC
Time frame: 0 - 144 hr
Cmax
Time frame: 0 - 144 hr
No study locations are listed for this record.
This study is status unknown, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Daewoong Pharmaceutical Co. LTD.